Categories AlphaGraphs, Earnings, LATEST, Other Industries
Pharmaceuticals unit lifts Johnson & Johnson results in Q3
Medical devices giant Johnson & Johnson (JNJ) reported higher revenue and income in Q3, driven by strong sales of pharmaceuticals products. The company posted earnings of $2.05 per share during the quarter, two cents higher than what analysts had expected. On a reported basis, earnings rose to $3.93 billion, or $1.44 per share, from $3.76 billion, or $1.37 per share in the year-over period.
The company reported net sales of $20.35 billion, up 3.6%. Analysts had, on an average expected $20.05 billion. Pharmaceuticals unit posted a better-than-expected sales of $10.35 billion during the quarter, as cancer drugs — Zytiga and Darzalex — made up for the weakness in the blockbuster arthritis drug Remicade.
Buoyed by the higher sales and income, the New Brunswick, New Jersey-based pharma giant raised its earnings outlook for the full year from a range of $8.07 to $8.17 per share to a range of $8.13 to 8.18 per share.
The Q3 results and guidance update sent Johnson & Johnson shares up 0.56% during pre-market trading on Tuesday.
Chief Executive Alex Gorsky said, “We are pleased with our strong third-quarter performance, which reflects continued above-market growth in our Pharmaceutical business, accelerating sales momentum in our Consumer business and consistent progress in our Medical Devices business.”
JNJ stock has lost 3.7% of its value so far this year, trailing S&P 500 index, which has gained 2.6%.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
IPO Alert: What to look for when Boundless Bio goes public
Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.
Nike (NKE) bets on innovation and partnerships to return to high growth
Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company
Walgreens Boots Alliance set to report earnings next week. Here’s what to expect
Walgreens Boots Alliance, Inc. (NASDAQ: WBA), the drug store chain that is expanding into a diversified healthcare provider, is on a restructuring drive aimed at better aligning the business with